BIONANO GENOMICS INC (BNGO) Fundamental Analysis & Valuation

NASDAQ:BNGO • US09075F4046

1.13 USD
-0.02 (-1.74%)
Last: Mar 12, 2026, 11:04 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BNGO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BNGO. BNGO was compared to 57 industry peers in the Life Sciences Tools & Services industry. BNGO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BNGO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. BNGO Profitability Analysis

1.1 Basic Checks

  • BNGO had negative earnings in the past year.
  • BNGO had a negative operating cash flow in the past year.
  • BNGO had negative earnings in each of the past 5 years.
  • BNGO had a negative operating cash flow in each of the past 5 years.
BNGO Yearly Net Income VS EBIT VS OCF VS FCFBNGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -48.81%, BNGO is doing worse than 82.46% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -77.49%, BNGO is doing worse than 77.19% of the companies in the same industry.
Industry RankSector Rank
ROA -48.81%
ROE -77.49%
ROIC N/A
ROA(3y)-99.22%
ROA(5y)-76.96%
ROE(3y)-203.87%
ROE(5y)-150.04%
ROIC(3y)N/A
ROIC(5y)N/A
BNGO Yearly ROA, ROE, ROICBNGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 45.97%, BNGO is in line with its industry, outperforming 43.86% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BNGO has declined.
  • BNGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-61.43%
GM growth 5Y-48.22%
BNGO Yearly Profit, Operating, Gross MarginsBNGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BNGO Health Analysis

2.1 Basic Checks

  • BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BNGO has been reduced compared to 1 year ago.
  • The number of shares outstanding for BNGO has been reduced compared to 5 years ago.
  • The debt/assets ratio for BNGO is higher compared to a year ago.
BNGO Yearly Shares OutstandingBNGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BNGO Yearly Total Debt VS Total AssetsBNGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -13.13, we must say that BNGO is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -13.13, BNGO is not doing good in the industry: 87.72% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.07 indicates that BNGO is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.07, BNGO is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -13.13
ROIC/WACCN/A
WACC63.71%
BNGO Yearly LT Debt VS Equity VS FCFBNGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.12 indicates that BNGO has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.12, BNGO perfoms like the industry average, outperforming 43.86% of the companies in the same industry.
  • A Quick Ratio of 1.82 indicates that BNGO should not have too much problems paying its short term obligations.
  • BNGO has a Quick ratio of 1.82. This is comparable to the rest of the industry: BNGO outperforms 43.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 1.82
BNGO Yearly Current Assets VS Current LiabilitesBNGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BNGO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 77.75% over the past year.
  • BNGO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.84%.
  • The Revenue has been growing by 24.89% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)77.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.38%
Revenue 1Y (TTM)-13.84%
Revenue growth 3Y19.62%
Revenue growth 5Y24.89%
Sales Q2Q%-9.75%

3.2 Future

  • Based on estimates for the next years, BNGO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.92% on average per year.
  • BNGO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.69% yearly.
EPS Next Y92.31%
EPS Next 2Y39.87%
EPS Next 3Y25.68%
EPS Next 5Y14.92%
Revenue Next Year-2.01%
Revenue Next 2Y10.35%
Revenue Next 3Y21.7%
Revenue Next 5Y22.69%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BNGO Yearly Revenue VS EstimatesBNGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
BNGO Yearly EPS VS EstimatesBNGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -500 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. BNGO Valuation Analysis

4.1 Price/Earnings Ratio

  • BNGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BNGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNGO Price Earnings VS Forward Price EarningsBNGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNGO Per share dataBNGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • BNGO's earnings are expected to grow with 25.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3Y25.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BNGO Dividend Analysis

5.1 Amount

  • No dividends for BNGO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BNGO Fundamentals: All Metrics, Ratios and Statistics

BIONANO GENOMICS INC

NASDAQ:BNGO (3/12/2026, 11:04:37 AM)

1.13

-0.02 (-1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners10.61%
Inst Owner Change262.17%
Ins Owners3.19%
Ins Owner Change0%
Market Cap11.50M
Revenue(TTM)28.72M
Net Income(TTM)-38.59M
Analysts80
Price Target7.65 (576.99%)
Short Float %12.85%
Short Ratio5.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.8%
Min EPS beat(2)18.39%
Max EPS beat(2)19.21%
EPS beat(4)3
Avg EPS beat(4)-14.6%
Min EPS beat(4)-158.66%
Max EPS beat(4)62.68%
EPS beat(8)6
Avg EPS beat(8)-2.56%
EPS beat(12)6
Avg EPS beat(12)-5.17%
EPS beat(16)7
Avg EPS beat(16)-8.67%
Revenue beat(2)1
Avg Revenue beat(2)0.88%
Min Revenue beat(2)-3.37%
Max Revenue beat(2)5.12%
Revenue beat(4)3
Avg Revenue beat(4)8.1%
Min Revenue beat(4)-3.37%
Max Revenue beat(4)29.08%
Revenue beat(8)5
Avg Revenue beat(8)3.75%
Revenue beat(12)8
Avg Revenue beat(12)2.71%
Revenue beat(16)11
Avg Revenue beat(16)3.13%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.24%
EPS NY rev (1m)0%
EPS NY rev (3m)0.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.26
EV/EBITDA N/A
EPS(TTM)-20.56
EYN/A
EPS(NY)-3.64
Fwd EYN/A
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS2.82
BVpS4.89
TBVpS4.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.81%
ROE -77.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.97%
FCFM N/A
ROA(3y)-99.22%
ROA(5y)-76.96%
ROE(3y)-203.87%
ROE(5y)-150.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-61.43%
GM growth 5Y-48.22%
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.12
Quick Ratio 1.82
Altman-Z -13.13
F-Score4
WACC63.71%
ROIC/WACCN/A
Cap/Depr(3y)12.46%
Cap/Depr(5y)12.34%
Cap/Sales(3y)4.56%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.38%
EPS Next Y92.31%
EPS Next 2Y39.87%
EPS Next 3Y25.68%
EPS Next 5Y14.92%
Revenue 1Y (TTM)-13.84%
Revenue growth 3Y19.62%
Revenue growth 5Y24.89%
Sales Q2Q%-9.75%
Revenue Next Year-2.01%
Revenue Next 2Y10.35%
Revenue Next 3Y21.7%
Revenue Next 5Y22.69%
EBIT growth 1Y59.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.38%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.63%
OCF growth 3YN/A
OCF growth 5YN/A

BIONANO GENOMICS INC / BNGO FAQ

Can you provide the ChartMill fundamental rating for BIONANO GENOMICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to BNGO.


Can you provide the valuation status for BIONANO GENOMICS INC?

ChartMill assigns a valuation rating of 1 / 10 to BIONANO GENOMICS INC (BNGO). This can be considered as Overvalued.


Can you provide the profitability details for BIONANO GENOMICS INC?

BIONANO GENOMICS INC (BNGO) has a profitability rating of 0 / 10.


What is the financial health of BIONANO GENOMICS INC (BNGO) stock?

The financial health rating of BIONANO GENOMICS INC (BNGO) is 4 / 10.